Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.56M | $3.22M | $3.66M | $7.32M | $27.6M | $65.6M | $96.7M | $107M | $65.2M | $66.4M |
| Revenue growth | — | 25.7% | 13.6% | 100.0% | 277.5% | 137.5% | 47.3% | 11.1% | -39.3% | 1.8% |
| Gross profit | — | — | — | — | $19.4M | $29.2M | $52.3M | $66.6M | $49.1M | $45.8M |
| Gross margin | — | — | — | — | 70.0% | 44.5% | 54.1% | 62.0% | 75.3% | 69.0% |
| Operating income | -$21.7M | -$20.1M | -$19.7M | -$16.8M | -$21.1M | -$58.9M | -$110M | -$17.1M | -$1.59M | -$7.83M |
| Operating margin | -847.0% | -624.7% | -538.2% | -230.1% | -76.5% | -89.7% | -113.7% | -15.9% | -2.4% | -11.8% |
| Net income | -$28.2M | -$22.5M | -$10.2M | -$27.1M | -$13.6M | -$58.3M | -$109M | -$17.1M | -$15.8M | -$13.6M |
| Net margin | -1099.7% | -698.7% | -278.3% | -370.6% | -49.3% | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% |
| EPS (diluted) | -$323.70 | -$48.30 | -$15.31 | -$3.48 | -$3.01 | -$3.48 | -$74.01 | -$5.11 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.7M | -$13.8M | -$15.9M | -$13.8M | -$28.4M | -$26.0M | -$28.8M | -$5.13M | -$1.39M | -$1.94M |
| Capital expenditures | $253K | $112K | $74.7K | $59.8K | $0.00 | $2.34M | $0.00 | — | $329K | $228K |
| Free cash flow | -$10.9M | -$13.9M | -$16.0M | -$13.9M | -$28.4M | -$28.3M | -$28.8M | — | -$1.72M | -$2.17M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.05M | $802K | $7.01M | $11.0M | $48.1M | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M |
| Total assets | $24.3M | $15.0M | $21.1M | $34.7M | $153M | $266M | $138M | $136M | $118M | $124M |
| Total liabilities | $14.3M | $11.0M | $7.64M | $27.6M | $58.3M | $128M | $93.3M | $97.1M | — | — |
| Long-term debt | — | — | — | — | — | — | $15.0M | $14.7M | $10.9M | $10.9M |
| Shareholders' equity | $10.1M | $4.00M | $13.4M | $7.09M | $95.0M | $138M | $44.3M | $39.4M | $27.7M | $19.0M |
| Retained earnings | -$46.6M | -$69.1M | -$79.3M | -$106M | -$120M | -$178M | -$287M | -$304M | -$320M | -$334M |
| Shares (wtd avg diluted) | 187K | 41.2B | 1.79M | 17.5M | 12.6M | 16.7M | 1.47M | 3.34M | 5.54M | 6.28M |
Every figure is extracted from AYTU BIOPHARMA, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.